Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):204-9. doi: 10.1016/j.ijrobp.2011.06.1975. Epub 2011 Oct 20.
To assess, through a retrospective review, clinical outcomes of patients with squamous cell carcinoma of the tonsil treated at the M. D. Anderson Cancer Center with unilateral radiotherapy techniques that irradiate the involved tonsil region and ipsilateral neck only.
Of 901 patients with newly diagnosed squamous cell carcinoma of the tonsil treated with radiotherapy at our institution, we identified 102 that were treated using unilateral radiotherapy techniques. All patients had their primary site of disease restricted to the tonsillar fossa or anterior pillar, with <1 cm involvement of the soft palate. Patients had TX (n = 17 patients), T1 (n = 52), or T2 (n = 33) disease, with Nx (n = 3), N0 (n = 33), N1 (n = 23), N2a (n = 21), or N2b (n = 22) neck disease.
Sixty-one patients (60%) underwent diagnostic tonsillectomy before radiotherapy. Twenty-seven patients (26%) underwent excision of a cervical lymph node or neck dissection before radiotherapy. Median follow-up for surviving patients was 38 months. Locoregional control at the primary site and ipsilateral neck was 100%. Two patients experienced contralateral nodal recurrence (2%). The 5-year overall survival and disease-free survival rates were 95% and 96%, respectively. The 5-year freedom from contralateral nodal recurrence rate was 96%. Nine patients required feeding tubes during therapy. Of the 2 patients with contralateral recurrence, 1 experienced an isolated neck recurrence and was salvaged with contralateral neck dissection only and remains alive and free of disease. The other patient presented with a contralateral base of tongue tumor and involved cervical lymph node, which may have represented a second primary tumor, and died of disease.
Unilateral radiotherapy for patients with TX-T2, N0-N2b primary tonsil carcinoma results in high rates of disease control, with low rates of contralateral nodal failure and a low incidence of acute toxicity requiring gastrostomy.
通过回顾性研究评估在 M.D.安德森癌症中心接受单侧放疗技术治疗的扁桃体鳞状细胞癌患者的临床结果,该技术仅照射受累的扁桃体区域和同侧颈部。
在我们机构接受放疗治疗的 901 例新诊断的扁桃体鳞状细胞癌患者中,我们确定了 102 例采用单侧放疗技术治疗的患者。所有患者的主要病变部位均局限于扁桃体窝或前柱,软腭受累<1cm。患者的 TX(n=17 例)、T1(n=52 例)或 T2(n=33 例)疾病,Nx(n=3 例)、N0(n=33 例)、N1(n=23 例)、N2a(n=21 例)或 N2b(n=22 例)颈部疾病。
61 例(60%)患者在放疗前接受了诊断性扁桃体切除术。27 例(26%)患者在放疗前切除了颈部淋巴结或进行了颈部清扫术。存活患者的中位随访时间为 38 个月。原发部位和同侧颈部的局部区域控制率为 100%。2 例患者出现对侧淋巴结复发(2%)。5 年总生存率和无病生存率分别为 95%和 96%。5 年无对侧淋巴结复发率为 96%。9 例患者在治疗期间需要使用饲管。在 2 例对侧复发的患者中,1 例仅接受了对侧颈部清扫术治疗,且无病存活。另一位患者表现为对侧舌根肿瘤和累及的颈部淋巴结,可能是第二原发肿瘤,并死于疾病。
对于 TX-T2、N0-N2b 期原发性扁桃体癌患者,单侧放疗可获得较高的疾病控制率,对侧淋巴结失败率较低,且需要胃造口术的急性毒性发生率较低。